DB
DMRA

Dmitry Balyasny’s Damora Therapeutics DMRA Stock Holding History

Dmitry Balyasny’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32M Sell
1,229,127
-218,873
-15% -$5.3M 0.04% 513
2026
Q1 		$37.5M Buy
+1,448,000
New +$37.2M 0.05% 441

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Dmitry Balyasny's DMRA Position: Q2 2026 in Review

Dmitry Balyasny reduced its Damora Therapeutics (DMRA) stake by 15% in Q2 2026, selling an estimated $5.3M and leaving 1,229,127 shares worth $32M. The position accounts for 0.04% of the portfolio, ranked #513.

Dmitry Balyasny first reported a position in DMRA in Q1 2026 and has held it in 2 quarters since. The position peaked at $37.5M in Q1 2026. 103 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Dmitry Balyasny held 1,229,127 shares of Damora Therapeutics worth $32M as of Q2 2026.
  • Dmitry Balyasny sold 218,873 Damora Therapeutics shares in Q2 2026, an estimated $5.3M.
  • Damora Therapeutics made up 0.04% of Dmitry Balyasny's portfolio in Q2 2026, its #513 holding.
  • Dmitry Balyasny first reported a position in Damora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Dmitry Balyasny's Damora Therapeutics position peaked at $37.5M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.